On December 12, 2022 Oncopeptides, a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, reported that the company presents new scientific data including one clinical abstract and three preclinical research posters at the Annual American Society of Hematology (ASH) (Free ASH Whitepaper) Meeting, ASH (Free ASH Whitepaper), in New Orleans, Louisiana, USA, on December 10-13 (Press release, Oncopeptides, DEC 12, 2022, View Source [SID1234646786]). The clinical abstract evaluated patients with multiple myeloma who were refractory to prior alkylators in the phase 3 OCEAN study. Data shows that melflufen is a safe and effective therapy in patients who are alkylator refractory, regardless of whether they received a prior autologous stem cell transplant or not.
The preclinical posters are based on the Company´s proprietary technology platforms for Peptide Drug Conjugate, PDC, and for NK-cell engagers, "Small Polypeptide based Killer Engagers", SPiKE and have been materialized through partnerships with leading research institutions in Finland, Norway, and Sweden.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very pleased to present preclinical data for OPDC3, next generation drug candidate from our PDC-platform, which has demonstrated significant activity in various hematological malignancies,"says Klaas Bakker, MD, PhD, Head of R&D and Chief Medical Officer. "Notably, for the first time we are also able to present preclinical data from our affibody-based NK-cell engager, that has strong potential to selectively activate NK-cells in multiple myeloma and other potential hematological malignancies."

Below is a brief description of the abstracts that have been accepted by the American Society of Hematology (ASH) (Free ASH Whitepaper). The abstracts are available at:
View Source

Scientific abstracts First author Publication Disposition
OCEAN (OP-103) Melflufen/dexamethasone compared with pomalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma – Subgroup analysis in patients refractory to prior alkylators F Schjesvold 5776 Abstract only
Potential role of NK cells and ABCB9 gene in melflufen resistance in multiple myeloma P. Sergeev 2673 Poster
The novel peptide drug conjugate OPDC3 is highly effective in different hematological malignancies J.J. Miettinen 4799 Poster
Affibody-based BCMA x CD-16 dual engagers for activation of NK-cells towards multiple myeloma K.A. Giang 4800 Poster